| First Author | Hemmi H | Year | 2002 |
| Journal | Nat Immunol | Volume | 3 |
| Issue | 2 | Pages | 196-200 |
| PubMed ID | 11812998 | Mgi Jnum | J:90979 |
| Mgi Id | MGI:3045627 | Doi | 10.1038/ni758 |
| Citation | Hemmi H, et al. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3(2):196-200 |
| abstractText | The imidazoquinoline compounds imiquimod and R-848 are low-molecular-weight immune response modifiers that can induce the synthesis of interferon-alpha and other cytokines in a variety of cell types. These compounds have potent anti-viral and anti-tumor properties; however, the mechanisms by which they exert their anti-viral activities remain unclear. Here we show that the imidazoquinolines activate immune cells via the Toll-like receptor 7 (TLR7)-MyD88-dependent signaling pathway. In response to the imidazoquinolines, neither MyD88- nor TLR7-deficient mice showed any inflammatory cytokine production by macrophages, proliferation of splenocytes or maturation of dendritic cells. Imidazoquinoline-induced signaling events were also abolished in both MyD88- and TLR7-deficient mice. |
